Nektar Therapeutics

Last updated
Nektar Therapeutics
FormerlyInhale Therapeutic Systems, Inc.
Company type Public
Industry Biopharmaceuticals
Founded1990;34 years ago (1990)
Headquarters San Francisco, California, U.S.
Products
Revenue US$90.1million (2023) [1]
Number of employees
137 (2024)
Website nektar.com

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. [2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances [3] , which improves drug characteristics like retention and solubility. [4] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. [2] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. [5]

Contents

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. [2] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc. [6]

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. [7] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. [8] As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion. [1]

As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. [9] Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees. [4]

Pipeline

Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. [10] The European Medicines Agency refused a marketing authorisation in 2017. [11]

Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, [12] Phase I results were announced in November 2016. [13] It is now in a phase 2 trial in combination with nivolumab for various advanced cancers. [14]

In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis. [4]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">ViroPharma</span> American pharmaceutical company

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">PTC Therapeutics</span> Pharmaceutical company

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

<span class="mw-page-title-main">United Therapeutics</span> American biotech company based in Maryland

United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

<span class="mw-page-title-main">Naloxegol</span> Medication used in the treatment for Opioid-Induced Constipation

Naloxegol is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia.

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

<span class="mw-page-title-main">CureVac</span> German bio-pharmaceutical company

CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.

<span class="mw-page-title-main">Lanabecestat</span> Chemical compound

Lanabecestat is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop the progression of Alzheimer's disease.

Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.

Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.

Rezpegaldesleukin is an experimental drug that modulates interleukin-2 and is in development for psoriasis, atopic dermatitis, and alopecia areata. Between 2017 and 2023, it was developed by a partnership of Eli Lilly and Company and Nektar Therapeutics, but the former left the partnership saying the drug lacked efficacy. Nektar disagreed with the interpretation of results, sued its former partner, and is continuing ahead with development.

References

  1. 1 2 "Nektar Therapeutics".
  2. 1 2 3 "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  3. ↑ "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  4. 1 2 3 Kansteiner, Fraiser (2024-11-04). "Nektar extends cash runway with $90M manufacturing plant sale". www.fiercepharma.com. Retrieved 2024-12-19.
  5. ↑ Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-01-22.
  6. ↑ "NKTR reuter.com". Reuters.com. Archived from the original on 2014-03-16. Retrieved 2014-03-16.
  7. ↑ "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  8. ↑ "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
  9. ↑ "Nektar Therapeutics Market Cap 2010-2024 | NKTR". www.macrotrends.net. Retrieved 2024-12-19.
  10. ↑ Kuznar, Wayne (28 June 2016). "Novel Agents are Targeting Drivers of TNBC: Several drug candidates in I-SPY2 have 'graduated' to later-phase studies". Medpage Today. Retrieved 23 February 2024.
  11. ↑ "Onzeald". European Medicines Agency. 2017-11-10.
  12. ↑ "Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine". Nektar Therapeutics. June 2, 2015. Archived from the original on 19 December 2017. Retrieved 25 June 2015.
  13. ↑ Martins, Ines (17 November 2016). "Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Study" . Retrieved 2020-11-12.
  14. ↑ Inman, Silas (12 November 2017). "NKTR-214/Nivolumab Combination Shows Promise in Early Study". OncLive. Retrieved 12 November 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.